Life Biosciences lands $80m to push cell reset therapy
Fresh funding backs the first human trial of a therapy designed to make older, damaged cells act younger…
Can the UK end animal testing sooner? MHRA unveils new support for alternatives
Image: © LightFieldStudios | iStock The UK’s medicines regulator is backing developers using non‑animal methods, offering early data…
Semaglutide Falls Short in Alzheimer’s Phase 3 Trials
Phase 3 trials show oral semaglutide failed to slow early Alzheimer’s progression, potentially limiting its expansion beyond metabolic…
Phase 3 Study: New Therapy Keeps Gastrointestinal Cancer Care on Course When Low Platelets Are an Obstacle
Newswise — MIAMI (March 16, 2026) – Cancer treatment is often described as a race against time. But…
Rewiring Immune System Offers New Path to Better Ovarian Cancer Treatment
Newswise — Researchers at the University of California San Diego and collaborators have discovered a new way to…
What Full Body MRIs and Cancer Blood Tests Really Offer
Mhttps://guardanthealth.com/pro…Y BROTHER’S EYESIGHT started to fail in February 2024. The problem came on suddenly: Text messages were blurry,…
SuppCo launches certification to verify actives in dietary supplements
The new program complements SuppCo’s TrustScore supplement quality rating system and builds on earlier testing initiatives, which revealed…
Why clinical trials on nutritional supplements are hard to design
Walk into any drugstore, natural market, or Costco and you’ll find a dazzling array of supplements promising everything…
Klothea initiates longevity-focused human trial of klotho therapy
Recruitment for Phase 1 trial of mRNA therapy begins in ‘special economic zone’ on the Caribbean island of…
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib,…
Fact Check Team: GLP-1 users getting rare pirate disease
WASHINGTON (TNND) — Popular GLP-1 weight-loss medications have helped millions of people shed pounds, but new research from…
Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals – Endpoints News
Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals Endpoints NewsCompass Pathways to Announce New…